{"id":"NCT03546842","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)","officialTitle":"A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-29","primaryCompletion":"2019-01-29","completion":"2019-01-29","firstPosted":"2018-06-06","resultsPosted":"2020-02-05","lastUpdate":"2020-02-25"},"enrollment":201,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Papillomavirus Infections","Uterine Cervical Neoplasms","Vulvar Neoplasms","Vaginal Neoplasms","Adenocarcinoma in Situ","Condylomata Acuminata"],"interventions":[{"type":"BIOLOGICAL","name":"9vHPV vaccine","otherNames":["V503","GARDASIL™9"]}],"arms":[{"label":"9vHPV vaccine","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and immunogenicity of V503 (GARDASIL™9, 9vHPV vaccine) administered to 9- to 26-year-old females and males in Vietnam. The study hypothesis states that V503 induces acceptable anti-human papillomavirus (HPV) 6, 11, 16, 18, 31, 33, 45, 52, and 58 seroconversion at 4 weeks postdose 3.","primaryOutcome":{"measure":"Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7","timeFrame":"4 weeks postdose 3 (Month 7)","effectByArm":[{"arm":"9vHPV Vaccine","deltaMin":100,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":18},"locations":{"siteCount":1,"countries":["Vietnam"]},"refs":{"pmids":["33844623"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":200},"commonTop":["Injection site pain","Injection site swelling"]}}